By Aidan Sowa, CEO and Founder, Frontier Industries | October 2026
No other medical specialty sells to people in this emotional condition. Your patients arrive carrying grief, hope, a calendar and usually a five figure sum of their own money, and they will research you at 2 a.m. with more intensity than any consumer in healthcare. This guide gives you one standard for judging an agency: can this team handle your success rate data, your patients' stories and your failures with the accuracy of a regulator and the tenderness of a good nurse. Almost every agency you meet can manage the tenderness. Fewer can manage the accuracy.
| Measure | Figure | Source |
|---|---|---|
| Adults worldwide who experience infertility | About 1 in 6, or 17.5 percent | WHO, 2023 |
| ART cycles reported in the United States, 2022 | 435,426 at 457 clinics | CDC, via 2022 success rates reporting |
| Live birth rate per intended retrieval, patients over 40, own eggs | 7.7 percent | CDC 2022 data |
I. Discrimen
Your success rate is a dataset before it is a headline
Every fertility clinic quotes a number. Almost every number is true and misleading at once, because the rate depends on the denominator: per cycle started, per retrieval, per transfer, per intended retrieval. CDC's 2022 reporting shows the spread plainly: for patients under 35 using their own eggs, about 49.7 percent of intended retrievals led to a live birth, while for patients over 40 the per transfer figure of 25.4 percent and the per intended retrieval figure of 7.7 percent describe the same medicine (CDC 2022 data summaries). A clinic quoting the kindest denominator is not lying. It is choosing which truth to rent.
Your agency must understand denominators cold, because journalists, regulators and rival clinics do. An agency that proposes leading your marketing with an unqualified success percentage has failed the only examination that matters in this specialty.
In fertility, the denominator is the ethics. Pick the flattering one and you have described your clinic accurately after all.
The choice also runs in the other direction, and good clinics know it. A programme accepting older patients, prior failures and complex diagnoses will post lower headline rates than a programme quietly screening for easy cases. That is not a marketing failure. It is a case mix, and it can be explained: who you accept, what you counsel, how your cumulative rates look across a full course of treatment rather than a single cycle. An agency that can build that explanation gives your physicians a public story worthy of the medicine they practice. One that cannot will keep pressuring your lab to chase a number by narrowing your doors, which is the moment marketing starts practising medicine without a licence.
II. Machina
Federal reporting built the machine your reputation runs on
Since the Fertility Clinic Success Rate and Certification Act of 1992, clinics report outcomes to the CDC, which publishes them through the National ART Surveillance System. The 2022 report covers 435,426 cycles performed for 251,542 patients at 457 clinics, resulting in 94,039 live birth deliveries and 98,289 babies, roughly 2.6 percent of all infants born in the United States that year (CDC 2022, as summarised in patient guidance). SART, the specialty's own society, publishes a parallel dataset that clinics quote when it flatters them more.
This machinery means your marketing lives beside an official record anyone can check, including the patient comparing you with the clinic across town at midnight. The strategic consequence is simple: the clinic whose public explanation of the data is clearest wins the trust of the most careful patients, who are disproportionately the ones who can pay. Your agency should be building that explanation, with age bands, diagnosis context and case mix caveats, not hiding from the tables.
The data is public. The only choice is whether your clinic or a forum explains it to your patients first.
III. Exemplum
The add-ons debate is your worked example in evidence honesty
Fertility medicine sells hope adjacent products: add-on treatments layered onto IVF cycles, many with thin evidence. Guideline bodies have started saying so in print. The European Society of Human Reproduction and Embryology's guidance, as summarised in patient facing reviews of the CDC data, recommends against routine use of several popular add-ons, including DHEA supplementation, for lack of supporting evidence (ESHRE guidance summary, 2025). Clinics divide sharply in public: some market add-ons as innovation, others publish their restraint as a virtue.
Watch which clinics gain durable reputations. The ones explaining what they will not sell, and why, accumulate a kind of authority money cannot purchase in this specialty, because every patient has met a clinic that sold them everything. Your agency should be able to draft your add-ons position, your donor programme ethics and your stance on success based pricing with the same care as your launch release. If they find those documents less exciting than a baby photo campaign, replace them.
The most persuasive sentence in fertility marketing is a treatment you declined to sell, explained well.
IV. Damnum
Mishandled stories cost more here than in any other specialty
Your patients' experiences are not content inventory. A testimonial gathered carelessly, a baby photo used past its consent, a success story implying a guarantee: each is a regulatory problem under the FTC's endorsement rules and a human problem that travels. In November 2023 the FTC sent warning letters to health influencers and trade associations over undisclosed paid endorsements in health content, a reminder that testimonial marketing in health categories is actively policed (FTC warning letters, reported 2023).
Price the emotional damage too. Failed cycles are the statistical majority experience in many age bands: CDC's own figures imply an average of 12.9 intended retrievals per live birth delivery for patients over 40 using their own eggs (CDC 2022 data). A clinic whose public voice only celebrates winners teaches its grieving majority that they are off brand. Those patients write the reviews your next patients read.
Your happiest patients make your photographs. Your saddest ones make your reputation.
Consider also the financial counselling layer, where reputational damage in this specialty quietly accumulates. Patients finance treatment through loans, shared risk programmes and refund packages whose terms they often grasp only after a failed cycle. A clinic whose marketing trumpets a money back guarantee while its consent process leaves the exclusions fuzzy has built a grievance with a payment schedule. Regulators in several states have tightened advertising and financing rules for exactly this pattern. Your agency should be reviewing how financing is described everywhere it appears, with the same suspicion it applies to success rates, because disappointed borrowers write the reviews that prospective patients trust most.
V. Genus
The controlling variable is how you treat uncertainty
Strip fertility marketing to one factor and it is uncertainty management. The science offers probabilities, never promises, and the WHO's first global estimate put lifetime infertility prevalence at about 17.5 percent of adults while stressing how underfunded and inaccessible treatment remains (WHO, 2023). Patients are not buying a baby. They are buying a fair process, honest odds and a team that tells them the truth at each branch point.
An agency fit for this specialty writes probabilities without flinching and hope without guaranteeing. Test candidates directly: hand them your real age banded outcomes and a brief to write the clinic's introductory page. The strong teams produce copy a patient can plan a life around. The weak ones produce copy a regulator can quote back at you.
Anyone can sell hope in this specialty. Selling honest odds is the scarce skill.
VI. Regio
The decision unit is rarely one person, and rarely only a patient
| Audience | What they are really deciding | Evidence they trust |
|---|---|---|
| Patients, usually researching as a couple | Whether to trust you with money, time and grief | CDC tables explained plainly, physician candour, peer communities |
| Referring OB-GYNs and GPs | Whether your failures become their embarrassment | Outcomes by diagnosis, communication back to the referrer |
| Donors and surrogates | Whether your clinic treats them as people or inventory | Programme ethics, transparent compensation and care standards |
| Employers and benefits managers | Whether fertility benefits deserve a place in the plan | Utilisation data, outcomes reporting, employee demand |
| State policymakers | Whether mandates or oversight should tighten | Your transparency record and complaint history |
Segmentation errors in this specialty are usually tonal. Content written for benefits managers reads as cold in patient feeds. Content written for patients reads as soft in payer meetings. Your agency needs distinct voices with one shared commitment: the numbers never change between rooms, only the explanation deepens.
The couple at midnight and the benefits director at noon must be able to compare your documents without finding two clinics.
One more audience sits inside your own walls and is usually forgotten in agency briefs: your clinical team. Nurses, embryologists and physicians read your marketing, and they grade it against what they watched happen that week. Copy that oversells makes their counselling conversations harder, because patients arrive anchored to sentences the team then has to gently dismantle in person. The morale and retention effects are real in a specialty short of experienced embryologists. A wise agency asks to interview your clinical staff before writing anything, and treats their corrections as the most valuable research in the engagement. Marketing your team respects is also, not coincidentally, marketing that stays accurate.
VII. Occasio
Access and financing are the open story, and employers are listening
The commercial centre of fertility is shifting from the clinic's website to the employer's benefits package. Coverage through employers and fertility benefits managers increasingly decides which clinics patients can use, while the WHO's reporting underlines how much of the world's fertility care is paid out of pocket or simply forgone (WHO, 2023). Clinics that can speak credibly to employers, about outcomes reporting, appropriate utilisation and employee experience, are building a referral channel their competitors barely address.
There is a second opening in male factor education. Male factors contribute to roughly half of infertility cases, yet clinic marketing still speaks almost exclusively to women. The clinic that addresses partners as patients, with dedicated content and services, doubles its doorway. An agency that spots these structural openings, rather than proposing another awareness month post, is thinking like an owner.
The next patient may arrive through a benefits portal, not a search result. Be findable in both.
VIII. Structura
A small clinic with honest tables beats a network with glossy ones
Fertility networks scale marketing budgets, but they cannot scale trust at the same rate, because trust in this specialty is local and personal: this embryologist, this physician, this lab's published record. CDC reporting makes the local record comparable across the country, which means a two physician clinic with strong age banded outcomes and lucid explanations can out compete a national brand in its own metro area.
Structure your agency choice to exploit that. You need depth in one metro and one specialty, not national reach. Interview for the team's knowledge of your state mandate environment, your actual competitors' CDC numbers, and the local referring community. Generalist healthcare fame is nearly worthless here. Specificity is the asset.
Patients do not choose a network. They choose the room where they will hear the hardest news of their lives.
IX. Consilium
Hire for data fluency and grief literacy, then check the creative work
| Agency option | Fit for a fertility clinic | Principal risk |
|---|---|---|
| Healthcare specialist agency | Handles regulated claims and clinical audiences well | May lack the emotional register this specialty demands |
| Consumer lifestyle agency | Beautiful patient facing storytelling | Most likely to misuse a rate or imply a guarantee |
| Fertility and women's health boutique | Knows the community, the language and the ethics debates | Small bench; verify crisis and payer facing range |
| In house coordinator with agency counsel | Continuity and daily community management | Strategy and data work can thin out |
| Digital marketing firm | Strong search and social mechanics | Content quality and claim control are chronic weaknesses |
| Criterion | Weight | Evidence to demand |
|---|---|---|
| Success rate data fluency | High | Have them explain your CDC table back to you, with denominators |
| Testimonial and consent practice | High | Their consent, typicality and disclosure process, in writing |
| Emotional register | High | Long form patient facing writing samples, judged by your nurses |
| Referrer and employer audiences | Medium | Materials aimed at OB-GYNs or benefits managers |
| Crisis steadiness | Medium | How they would handle a lab incident story |
The rest of the healthcare guides live in the resources index, and engagement structures are explained on the public relations services page. Clinics building employer channels should also read the guide for health insurance companies, whose buyers control more of your demand each year.
Frequently asked questions
Can we advertise our success rate?
You can publish it, with its denominator, age band and time period attached, consistent with your CDC and SART reporting. What you cannot responsibly do is quote the highest available framing without context. Your agency should maintain a single approved statistics sheet that every channel works from.
How should we use patient stories and baby photos?
With written, revocable consent, clear disclosure of any incentive, and no implication that an individual story represents a typical outcome. Rotate whose stories you tell, including journeys that did not end in a birth where the patient wishes to share them. Your community can detect a highlight reel, and discounts it.
How should we handle questions about a specific doctor's results?
Carefully, because patients increasingly research physicians as individuals while the reported data describes programmes. Point patients to the clinic level CDC figures, explain how case assignment works in your practice, and let your physicians discuss their approach and experience in consultation rather than in advertising. Your agency should keep individual marketing inside the same evidence discipline as the clinic's own claims.
Our outcomes are mid table. Is honest marketing still possible?
Yes, and it may be your strongest position. Case mix matters: clinics accepting poor prognosis patients post lower rates while doing harder medicine. Explain your mix, your counselling honesty and your per patient approach. Many patients are searching for a clinic that will level with them, not a league table winner.
What should we say about add-ons we offer?
State the evidence status of each, who it is and is not for, and what it costs, in the same place you sell it. If a guideline body recommends against routine use, your page should acknowledge the debate rather than pretend it does not exist. Patients cross check, and they reward candour.
How do we market egg freezing without exploiting anxiety?
Sell information and timing honestly: success depends heavily on age at freezing and number of eggs stored, and no storage programme guarantees a future birth. Campaigns built on fear of delay convert well for a quarter and poison a brand for years.
What do referring physicians want from our communications?
Prompt, complete feedback on their patients, realistic shared expectations, and no surprises in the press. A clinic that reports back well gets referrals that no consumer campaign can buy. Your agency should treat referrer communication as a first class channel.
How fast should we respond to a negative review describing a failed cycle?
Promptly, privately and without defensiveness. Acknowledge the grief, invite direct contact, and never discuss clinical details in public. Your reply is written for the hundred future patients who will read it in silence.
How this guide was built
The outcome figures here come from the CDC's National ART Surveillance System reporting for 2021 and 2022 as summarised in patient facing analyses, the WHO's 2023 global infertility prevalence report, ESHRE guideline summaries and FTC endorsement enforcement reporting. The limits matter: CDC clinic data lags by roughly two years and reflects case mix as much as quality, prevalence estimates are global rather than national, and guideline positions on add-ons evolve as trials report. Build your approved statistics from your own current CDC submission, and treat every number in this guide as a method lesson rather than a figure to copy into your marketing.
X. Incipe
Where Frontier Industries fits in this decision
Frontier Industries works with healthcare providers whose marketing has to survive both regulatory reading and deeply personal scrutiny, and fertility clinics face the most personal version of that test in this library. The practice is built around approved statistics, consent led storytelling and voices calibrated per audience, patient, referrer and employer. You can meet the team on the about page, and clinics serving older patients will find overlap in the guide for senior care providers.
Bring your current CDC table and the page of your website you are least proud of. Open with the industry campaign page, or call 401-219-4207 and ask for the clinic lead.
Sources
1. World Health Organization, 1 in 6 people globally affected by infertility, 2023. https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-by-infertility 2. CoParents, IVF Success Rate: 7 Essential Stats Every Patient Must Know, summarising CDC and SART national data. https://www.coparents.com/blog/fertility/ivf-success-rate/ 3. Fertility Clinic Finder, IVF Success Rates by Age: CDC 2022 Data. https://fertility-clinic-finder.com/blog/ivf-success-rates-by-age 4. PlainFertility, Compare IVF Clinic Success Rates, built on CDC National ART Surveillance System data. https://plainfertility.com/ 5. TheWorldData, IVF Treatment Statistics in US, data source CDC National ART Surveillance System 2022. https://theworlddata.com/ivf-treatment-statistics-in-us/ 6. Cada, 60+ IVF statistics, success rates, and more, citing CDC Fertility Clinic Success Rates Report 2021. https://cada.com/en/blog/ivf-statistics/ 7. WorldMetrics, IVF Success Statistics, compiling CDC 2022 and SART 2023 figures. https://worldmetrics.org/ivf-success-statistics/ 8. Zipdo, Fertility Industry Statistics, compiling CDC and SART reporting. https://zipdo.co/fertility-industry-statistics/ 9. Clinical Advisor, WHO Releases First Guideline on Management of Infertility, 2025. https://www.clinicaladvisor.com/features/who-releases-first-guideline-on-management-of-infertility/ 10. Zwillgen, FTC Announces Warning Letters for Violations of Guides for Endorsements and Testimonials, 2023. https://www.zwillgen.com/ftc-state-ag/ftc-warning-letters-violations-endorsements-testimonials/